Value Drug Co. v. Takeda Pharm., U.S.A.

Full title: VALUE DRUG COMPANY v. TAKEDA PHARMACEUTICALS, U.S.A., INC., et al.

Court: United States District Court, E.D. Pennsylvania

Date published: Feb 28, 2023

Civil Action 21-3500 (E.D. Pa. Feb. 28, 2023)

Opinion

Civil Action 21-3500

02-28-2023

VALUE DRUG COMPANY v. TAKEDA PHARMACEUTICALS, U.S.A., INC., et al.

KEARNEY, J.

ORDER

KEARNEY, J.

AND NOW, this 28^th day of February 2023, upon considering Plaintiffs renewed Motion to certify a class (ECF Doc. No. 700), Defendants' Response (ECF Doc. No. 736), Plaintiffs Reply (ECF Doc. No. 759), pre-hearing Memoranda (ECF Doc. Nos. 834, 836), following extensive oral argument, post-hearing Memoranda (ECF Doc. Nos. 869, 870), and for reasons in the accompanying Memorandum, it is ORDERED:

1. Plaintiffs Motion (ECF Doc. No. 700) is DENIED; and

2. Lead trial counsel shall meaningfully meet and confer so as to allow Defendants, consistent with our January 18, 2023 Order (ECF Doc. No. 751), to file a joint Notice not exceeding five pages on or before March 10, 2023 identifying the parties' proposal(s) for our continuing progress towards trial including the number of anticipated trial days.